Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iso-phenylcyclopentylamine hydrochloride
- Development stage
- Unknown
- Lead developer
- Alexander Shulgin Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
iso-phenylcyclopentylamine hydrochloride is a small molecule triple monoamine reuptake inhibitor (TRI) developed by Silver Valley Pharmaceutical. It is designed to simultaneously inhibit the reuptake of dopamine, norepinephrine, and serotonin by targeting their respective transporters: the dopamine transporter (DAT), the norepinephrine transporter (NET), and the serotonin transporter (SERT). By increasing the synaptic concentrations of these three neurotransmitters, the compound aims to modulate central nervous system pathways involved in satiety and energy expenditure. It was primarily investigated as a potential treatment for obesity. Currently, the development status of this program is listed as pending, and it is considered potentially inactive or on hold.
- Other names
- iso-phenylcyclopentylamine hydrochloride
02
Targets
DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on iso-phenylcyclopentylamine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iso-phenylcyclopentylamine hydrochloride.